Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepak L Bhatt

Showing results (911-920 of 1,708) with videos related to

Pageof 171
Sort By:
Circulation. Cardiovascular Quality and Outcomes|September 6, 2012
Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarctionKeith A Somma, Deepak L Bhatt, Gregg C Fonarow, et al.
Circulation. Cardiovascular Quality and Outcomes|June 21, 2012
Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarctionSumeet Subherwal, Deepak L Bhatt, Shuang Li, et al.
Research and Practice in Thrombosis and Haemostasis|November 9, 2022
Case-fatality rate of major bleeding events in patients on dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and meta-analysisTobias Tritschler, Anuj Patel, Noémie Kraaijpoel, et al.
NPJ Digital Medicine|August 24, 2024
Multimodal fusion learning for long QT syndrome pathogenic genotypes in a racially diverse populationJoy Jiang, Ha My Thi Vy, Alexander Charney, et al.
European Heart Journal|February 23, 2019
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trialJonas Oldgren, Philippe Gabriel Steg, Stefan H Hohnloser, et al.
Journal of the American Heart Association|February 13, 2017
Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection FractionLauren G Gilstrap, Gregg C Fonarow, Akshay S Desai, et al.
American Heart Journal|June 20, 2017
Impact of continuous positive airway pressure and oxygen on health status in patients with coronary heart disease, cardiovascular risk factors, and obstructive sleep apnea: A Heart Biomarker Evaluation in Apnea Treatment (HEARTBEAT) analysisEldrin F Lewis, Rui Wang, Naresh Punjabi, et al.
Circulation|June 3, 2010
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialPeter B Berger, Deepak L Bhatt, Valentin Fuster, et al.
Circulation. Heart Failure|February 13, 2016
Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure RegistryPrateeti Khazanie, Li Liang, Lesley H Curtis, et al.
American Heart Journal|February 26, 2022
Design and rationale for the supermarket and web-based intervention targeting nutrition (SuperWIN) for cardiovascular risk reduction trialSarah C Couch, Robert N Helsley, Francesca U Siegel, et al.
Pageof 171

Showing results (911-920 of 1,708) with videos related to

Sort By:
Pageof 171
Circulation. Cardiovascular Quality and Outcomes|September 6, 2012
Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarctionKeith A Somma, Deepak L Bhatt, Gregg C Fonarow, et al.
Circulation. Cardiovascular Quality and Outcomes|June 21, 2012
Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarctionSumeet Subherwal, Deepak L Bhatt, Shuang Li, et al.
Research and Practice in Thrombosis and Haemostasis|November 9, 2022
Case-fatality rate of major bleeding events in patients on dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and meta-analysisTobias Tritschler, Anuj Patel, Noémie Kraaijpoel, et al.
NPJ Digital Medicine|August 24, 2024
Multimodal fusion learning for long QT syndrome pathogenic genotypes in a racially diverse populationJoy Jiang, Ha My Thi Vy, Alexander Charney, et al.
European Heart Journal|February 23, 2019
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trialJonas Oldgren, Philippe Gabriel Steg, Stefan H Hohnloser, et al.
Journal of the American Heart Association|February 13, 2017
Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection FractionLauren G Gilstrap, Gregg C Fonarow, Akshay S Desai, et al.
American Heart Journal|June 20, 2017
Impact of continuous positive airway pressure and oxygen on health status in patients with coronary heart disease, cardiovascular risk factors, and obstructive sleep apnea: A Heart Biomarker Evaluation in Apnea Treatment (HEARTBEAT) analysisEldrin F Lewis, Rui Wang, Naresh Punjabi, et al.
Circulation|June 3, 2010
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialPeter B Berger, Deepak L Bhatt, Valentin Fuster, et al.
Circulation. Heart Failure|February 13, 2016
Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure RegistryPrateeti Khazanie, Li Liang, Lesley H Curtis, et al.
American Heart Journal|February 26, 2022
Design and rationale for the supermarket and web-based intervention targeting nutrition (SuperWIN) for cardiovascular risk reduction trialSarah C Couch, Robert N Helsley, Francesca U Siegel, et al.
Pageof 171